Aurobindo Pharma’s Covid Vaccine plans get a setback

The Company is one of the most active news providers amongst the Indian pharma players. It has now informed that its COVID-19 vaccine UB-612 programme hasn’t progressed, as its partner Vaxxinity failed to secure the emergency use authorization (EUA) in Taiwan. Key points to note – Approval in Taiwan was denied in August as the … Read more

Abbott introduces single-dose formulation of carbetocin in India

Drug major Abbott on Tuesday said it has launched room-temperature-stable, single-dose formulation of carbetocin in India to help in the prevention of postpartum haemorrhage (PPH). PPH refers to excessive blood loss of 500 ml or more after vaginal delivery and 1,000 ml or more after a caesarean procedure, within 24 hours of childbirth. Although preventable, … Read more

Abbott is more than 100 years old in India

Abbott, one of the most admired healthcare global company is also one of the oldest in India. It was established in India in 1910. When I first read about it, I couldn’t believe it and hence thought of sharing. Also for ease of reference, Abbott originally an American Company was founded in 1888. i.e., 22 … Read more

Pharmaceutical firms turn focus to inhalation products for Covid-19

After injectables and oral solid drugs, now pharmaceutical firms are focusing on coming up with re-purposed inhalation products for Covid-19. While drug major Lupin is working on a remdesivir powder for inhalation, Mumbai-based Glenmark has tied up with a Canadian Biotech firm for Nitric Oxide nasal spray that reduces Sars-CoV-2 viral load and thus transmission. … Read more

Tech Mahindra expects to begin trials for planned COVID drug in 3-4 months

After receiving the patent for a particular molecule, according to a senior official. Markers Lab, the research and development arm of the IT company, is working on developing the drug. The company along with Reagene Biosciences has filed for the patent for a molecule that can be used to develop a drug against coronavirus. “We … Read more